EVMNHealthcare · BiotechnologyThe 10 Wall Street analysts covering Evommune, Inc. hold a median 12-month price target of $24 — +127.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Evommune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (64): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (0): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EVMN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +127.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 Sept 2026 | Leerink Partners | Maintains | Outperform | $28 → $22 |
| 9 Sept 2026 | RBC Capital | Maintains | Outperform | $29 → $21 |
| 26 Aug 2026 | Needham | Initiates | Buy | $28 |
| 26 Aug 2026 | Needham | Initiates | Buy | — |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $30 → $29 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 30 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 30 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 30 June 2026 | Morgan Stanley | Maintains | Overweight | — |
| 30 June 2026 | Morgan Stanley | Maintains | Overweight | $55 → $26 |
| 29 June 2026 | William Blair | Downgrade | Market Perform | — |
| 29 June 2026 | William Blair | Downgrade | Market Perform | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 10 Apr 2026 | RBC Capital | Reiterates | Outperform | — |
| 18 Mar 2026 | Clear Street | Initiates | Buy | — |
| 18 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EVMN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 6% of US stocks
Cheaper than 60% of US stocks
Cheaper than 71% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Evommune, Inc. has a market value of $382.5M and an enterprise value of $190.4M.
Revenue in the twelve months to 30 June 2026: $10.0M.
Net income over the same four quarters: −$94.7M, a −946.7% net margin.
Diluted earnings per share, trailing twelve months: $−3.37.
Free cash flow in the twelve months to 30 June 2026: −$74.7M.
Trailing P/E: −0.9×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Evommune, Inc. employs 48 people — $208K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Evommune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Evommune announced topline results from its Phase 2b dose-ranging trial of oral EVO756 for moderate-to-severe atopic dermatitis, which did not meet expectations, leading the company to halt its atopic dermatitis program.
Why it matters — The discontinuation of the EVO756 atopic dermatitis program removes a key pipeline candidate for the clinical-stage company, affecting its development roadmap.
Evommune announced it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending shares down 24% in aftermarket trading.
Why it matters — The discontinuation of a lead pipeline candidate and the resulting 24% share decline represents a significant setback for Evommune's development prospects.
Evommune announced top-line results from its randomized, double-blind, placebo-controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of its oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe atopic dermatitis. The announcement provides initial data from this clinical study of the company's developmental therapy.
Why it matters — Phase 2b data for EVO756 is a key clinical milestone for Evommune's pipeline in chronic inflammatory disease, informing investors about the therapy's efficacy and safety profile.
Evommune, Inc., a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, announced its financial results for the second quarter ended June 30, 2026, and provided a business update. The company highlighted the lack of first-line oral options for atopic dermatitis patients that combine lesion control, itch relief, and tolerability.
Why it matters — EVOMN watchers would care because the company's quarterly disclosure and business update provide insight into its clinical pipeline and its positioning in the atopic dermatitis treatment market.
Evommune announced the first patient was dosed in its Phase 2b clinical trial of EVO756, an oral small molecule MRGPRX2 inhibitor, for the prophylactic treatment of migraine.
Why it matters — This milestone advances a key pipeline candidate into later-stage clinical testing for a new indication, expanding Evommune's potential therapeutic reach beyond inflammatory diseases.
The 10 Wall Street analysts covering Evommune, Inc. have a median 12-month price target of $24, with estimates ranging from $18 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Evommune, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evommune, Inc. 10 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Evommune, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (64 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +127.7% from the last close, and Ticker Nerd's factor model ranks Evommune, Inc. 10 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Evommune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $30 over the next 12 months.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases.
The most recent item we track (Benzinga, 9 Sept 2026): "Evommune Halts Atopic Dermatitis Program Following Trial Failure". Evommune announced topline results from its Phase 2b dose-ranging trial of oral EVO756 for moderate-to-severe atopic dermatitis, which did not meet expectations, leading the company to halt its atopic dermatitis program.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing novel treatments designed to address key drivers of inflammation, with current programs centered on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its pipeline includes product candidates such as EVO756 and EVO301, which are being developed to target immune pathways involved in these conditions. Evommune’s work is positioned within the broader immunology and inflammation markets, where it aims to support more precise treatment options for patients with persistent inflammatory disorders. Based in Palo Alto, California, Evommune emphasizes research-driven drug development across small-molecule and biologic approaches.
CEO Mr. Luis C. Pena · 48 employees · United States · https://www.evommune.com
